You contemplate your frustration for a solid 5 minutes, then either give up or ping the person next to you that has a Mac.
#REVIEW TOOLBOX FOR KEYNOTE TRIAL#
Pts with a history of invasive malignancy that was diagnosed and/or treated within the last 5 y are excluded. TPS602 Background: Recently presented data from the I-SPY 2 trial showed that pembrolizumab, a humanized, antiPD-1 monoclonal antibody, significantly increased the pathologic complete response (pCR) rate in early-stage TNBC, when combined with neoadjuvant chemotherapy (Nanda et al. Chances are you’ve experienced this scenario you were sent a Keynote presentation, which you need to review and pull content from, but you are operating on a PC. Adequate organ function and ECOG PS 0-1 are required. Pts with inflammatory breast cancer or bilateral or multifocal primary tumors are allowed.
Eligible pts are aged ≥18 y with previously untreated, locally advanced, nonmetastatic TNBC.
.jpg "review toolbox for keynote")
Secondary end points include safety, OS, and pCR rate by ypT0 ypN0, and ypT0/Tis in all pts and OS, EFS, and pCR rate by ypT0/Tis ypN0, ypT0 ypN0, and ypT0/Tis in pts with PD-L1+ tumors (combined positive score, CPS≥1). Primary end points are pCR rate using ypT0/Tis ypN0 and EFS.
All cycles = 21d treatment is up to 17 cycles or until disease progression/unacceptable toxicity. Definitive surgery will be 3-6 wk after the last cycle, then pts will receive 9 cycles of pembro (200 mg Q3W) or placebo as adjuvant therapy. In arm 1, pts will receive 4 cycles of pembro 200 mg Q3W+paclitaxel (80 mg/m 2 QW on d 1, 8, 15)+carboplatin (AUC 5 Q3W on d 1 or AUC 1.5 QW on d 1, 8, 15) and then 4 cycles of pembro++cyclophosphamide (600 mg/m 2 Q3W on d 1) as neoadjuvant therapy. Stratification will be by tumor nodal status (positive vs negative), size (T1/T2 vs T3/T4), and carboplatin regimen choice (Q3W vs QW). Methods: Approximately 855 pts with TNBC, defined as combined primary tumor (T) and regional lymph node (N) staging per AJCC (investigator-assessed: T1c N1-2, T2-4 N0-2), will be randomly assigned to 1 of 2 arms. KEYNOTE-522 (NCT03036488) is a phase III study of pembro+chemo vs placebo+chemo as neoadjuvant treatment, followed by pembro vs placebo as adjuvant treatment in pts with TNBC.
#REVIEW TOOLBOX FOR KEYNOTE SERIES#
This Keynote series covers tips for using the app, giving stand-out presentations, as well as beautiful Keynote templates and themes. With beautiful layout tools and typography, it can give your presentation an edge. Truly money well-spent.Background: Recently presented data from the I-SPY 2 trial showed that pembrolizumab, a humanized, anti–PD-1 monoclonal antibody, significantly increased the pathologic complete response (pCR) rate in early-stage TNBC, when combined with neoadjuvant chemotherapy (Nanda et al. Keynote, part of Apples iWork suite, is a presentation tool of the pros. These collections are like Colorforms and you just grab the ones that work together well for whatever you are doing. Field Days or distance learning (Yeah, that is going to be a new thing going forward) are just two quick examples of specific requests I would make but I am also sure I can grab other images and items from previous templates to create something original. That is why I will not take away points for themes they have not yet gotten to which are useful in elementary school. I really enjoy that I spent for the lifelong package and I sometimes am getting updates between uses! Updates usually are bringing more content with new themes. What I found was greqt graphics that I could use not just within Keynote, but I could us to create content which made printouts look like it was all part of one cohesive thought. I bought this when I had gone back to school to be a teacher figuring I would be making presentations not just for school, but when I was teaching.
0 kommentar(er)
